J&J's canagliflozin may raise heart risks

01/9/2013 | USA Today · Bloomberg

An FDA panel on Tuesday concluded that Johnson & Johnson's experimental diabetes drug canagliflozin may slightly raise the odds of heart attack, stroke or death as it increased bad cholesterol levels in patients compared with two other diabetes medications. The drug, part of a class known as SGLT2 inhibitors, might help control blood glucose levels in patients with type 2 diabetes, as well as aid in weight loss and lowering blood pressure, a company spokesman said.

View Full Article in:

USA Today · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations